Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + azacitidine in newly diagnosed MDS-EB1/EB2 (Phase Ib/II, single arm)
ChiCTR2200065167Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor and azacitidine in myelodysplastic syndrome with excess blasts (MDS-EB), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Maximum tolerable dose (MTD) of selinexor + azacitidine, Recommended dose for Phase II (RP2D) and 1 more. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
selinexorazacitidine
03
Conditions
myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on ChiCTR2200065167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065167.